Linerixibat is primarily investigated for its potential in treating pruritus, a common and distressing symptom associated with chronic liver diseases such as primary biliary cholangitis (PBC). It functions as an ileal bile acid transporter (IBAT) inhibitor, reducing the reabsorption of bile acids in the intestine. By decreasing the circulating bile acids, it alleviates the itching sensation that significantly impacts the quality of life in patients with PBC. Clinical trials have shown promising results in reducing pruritus severity, making it a potential therapeutic option for patients who do not respond adequately to standard treatments. Its targeted mechanism offers a novel approach to managing this challenging symptom in liver disease patients.